# OnCo record pharmaessentia (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/pharmaessentia/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "pharmaessentia" ;
  schema:name "PharmaEssentia"@en ;
  schema:alternateName "PharmaEssentia Corporation"@en, "藥華醫藥"@en ;
  schema:description "PharmaEssentia is a Taiwanese biotechnology company whose long-acting interferon ropeginterferon alfa-2b (Besremi) is approved for polycythaemia vera, a chronic blood cancer, in the United States, Europe and Asia."@en ;
  schema:url <https://onco.cc/companies/pharmaessentia/>, <https://www.pharmaessentia.com> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://www.pharmaessentia.com>, <https://clinicaltrials.gov/search?lead=PharmaEssentia>, <https://en.wikipedia.org/wiki/PharmaEssentia> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "TW" ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:drugs <https://onco.cc/drugs/ropeginterferon-alfa-2b/> ;
  onco:terms <https://onco.cc/terms/pivotal-trial/>, <https://onco.cc/terms/clinical-trial/> ;
  onco:trials <https://onco.cc/trials/nct06468033/>, <https://onco.cc/trials/nct05481151/>, <https://onco.cc/trials/nct05485948/>, <https://onco.cc/trials/nct05482971/>, <https://onco.cc/trials/nct04285086/> .